Using Tenofovir Disoproxil Fumarate to treat Parkinson's Disease
Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
This study tests if a medication called tenofovir disoproxil fumarate can help improve movement symptoms in people with early-stage Parkinson's disease.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06356662 on ClinicalTrials.gov |
What this trial studies
This study evaluates the efficacy and safety of tenofovir disoproxil fumarate in patients with early-stage Parkinson's disease. It compares changes in motor symptoms and the occurrence of adverse reactions between patients taking the drug and those not taking it at various time points. The study aims to determine whether this medication can improve symptoms associated with Parkinson's disease.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with early-stage Parkinson's disease, specifically those with a Hoehn Yahr stage of 1 to 2.5 and a Mini-Mental State Examination (MMSE) score of 24 or higher.
Not a fit: Patients with other neurological disorders, severe psychiatric conditions, or significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for managing Parkinson's disease symptoms.
How similar studies have performed: While the use of tenofovir disoproxil fumarate in Parkinson's disease is a novel approach, similar studies targeting neurodegenerative conditions have shown promise in the past.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24 Exclusion Criteria: * 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders 2: Or have received deep brain stimulation and other brain surgery 3: Abnormal liver and kidney function 4: Infected with chronic hepatitis B or AIDS (HIV-1 infection) 5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence 6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor 7: Pregnant or lactating women and seniors over 65 years of age 8: Allergy or other contraindications to the investigational drug
Where this trial is running
Hangzhou, Zhejiang
- Guohua Zhao — Hangzhou, Zhejiang, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.